ArticleDiabetes care2013
Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes?: Insulin therapy has proven itself and is considered the mainstay of treatment.
Article in Diabetes care, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 49 citations in OpenAlex.
- A Randomized Controlled Study Comparing a DPP4 Inhibitor (Linagliptin) and Basal Insulin (Glargine) in Patients With Type 2 Diabetes in Long-term Care and Skilled Nursing Facilities: Linagliptin-LTC Trial.Journal of the American Medical Directors Association · 2018Trial
- Prescription appropriateness of anti-diabetes drugs in elderly patients hospitalized in a clinical setting: evidence from the REPOSI Register.Internal and emergency medicine · 2023Article
- Management of diabetes and hyperglycaemia in the hospital.The lancet. Diabetes & endocrinology · 2021 · on this mapReview
- Management of Inpatient Hyperglycemia and Diabetes in Older Adults.Clinics in geriatric medicine · 2020Review
- Role of incretin-based therapy in hospitalized patients with type 2 diabetes.Journal of diabetes investigation · 2020Article
- Debate on Insulin vs Non-insulin Use in the Hospital Setting-Is It Time to Revise the Guidelines for the Management of Inpatient Diabetes?Current diabetes reports · 2019Review
- Use of Insulin in the Inpatient Setting: Need for Continued Use.Current diabetes reports · 2019Review
- Use of Linagliptin for the Management of Medicine Department Inpatients with Type 2 Diabetes in Real-World Clinical Practice (Lina-Real-World Study).Journal of clinical medicine · 2018Article
- Update on Glucose Management Among Noncritically Ill Patients Hospitalized on Medical and Surgical Wards.Journal of the Endocrine Society · 2017Review
- Management of Inpatient Hyperglycemia and Diabetes in Older Adults.Diabetes care · 2017Review
- Management of hospitalized type 2 diabetes mellitus patients.Journal of translational internal medicine · 2016Article
- A practical and evidence-based approach to management of inpatient diabetes in non-critically ill patients and special clinical populations.Journal of clinical & translational endocrinology · 2016Review
- The potential role of incretin therapy in the hospital setting.Clinical diabetes and endocrinology · 2015Article
- Pharmacotherapy for Hyperglycemia in Noncritically Ill Hospitalized Patients.Diabetes spectrum : a publication of the American Diabetes Association · 2014Article
- The use of non-insulin anti-diabetic agents to improve glycemia without hypoglycemia in the hospital setting: focus on incretins.Current diabetes reports · 2014Review
- Understanding hypoglycemia in hospitalized patients.Diabetes management (London, England) · 2014Article
- Hyperglycemia in the intensive care unit: is insulin the only option?Critical care (London, England) · 2013Article
- Glycaemic efficacy and safety of linagliptin for the management of non-cardiac surgery patients with type 2 diabetes in a real-world setting: Lina-Surg study.Annals of medicineObservational
Corrections and comments
- Commented on by
- Commented on by
- Comment on
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Significant data suggest that overt hyperglycemia, either observed with or without a prior diagnosis of diabetes, contributes to an increase in mortality and morbidity in hospitalized patients. In this regard, goal-directed insulin therapy has remained as the standard of care for achieving and maintaining glycemic control in hospitalized patients with critical and noncritical illness. As such, protocols to assist in management of hyperglycemia in the inpatient setting have become commonplace in hospital settings. Clearly, insulin is a known entity, has been in clinical use for almost a century, and is effective. However, there are limitations to its use. Based on the observed mechanisms of action and efficacy, there has been a great interest in using incretin-based therapy with glucagon-like peptide-1 (GLP-1) receptor agonists instead of, or complementary to, an insulin-based approach to improve glycemic control in hospitalized, severely ill diabetic patients. To provide an understanding of both sides of the argument, we provide a discussion of this topic as part of this two-part point-counterpoint narrative. In the point narrative preceding the counterpoint narrative below, Drs. Schwartz and DeFronzo provide an opinion that now is the time to consider GLP-1 receptor agonists as a logical consideration for inpatient glycemic control. In the counterpoint narrative provided below, Drs. Umpierrez and Korytkowski provide a defense of insulin in the inpatient setting as the unquestioned gold standard for glycemic management in hospitalized settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.